Allogeneic Stem Cell Transplant for CLL

You may not be if

• A 10/10 HLA matched (high resolution typing at A, B, C, DRB1, DQ1) sibling or unrelated donor
• Left ventricular ejection fraction (EF) \> 40%
• Forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and corrected diffusion capacity of the lung for carbon monoxide (DLCO) \> 40%
• Serum creatinine \< 1.6 mg/dL
• Serum bilirubin \< 2 X upper limit of normal
• serum glutamate pyruvate transaminase (SGPT) \< 2X upper limit of normal
• Voluntary signed, written Institutional Review Board (IRB)-approved informed consent
• Men and women of reproductive potential must agree to follow accepted birth control methods for the duration of the study. Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. Male subject agrees to use an acceptable method for contraception for the duration of the study
• Patient with active central nervous system (CNS) disease
• Pregnant (positive beta human chorionic gonadotropin \[HCG\] test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization) or currently breast-feeding. Pregnancy testing is not required for post-menopausal or surgically sterilized women
• Known infection with human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV)-I, hepatitis B, or hepatitis C
• Active uncontrolled bacterial, viral or fungal infections
• Patient has received other investigational drugs within 1 week before enrollment